Default company panoramic image
Logo

Aciex Respiratory Therapeutics

Redevelop novel form of fluticasone (API in $1 billion Flovent) from BID to QD asthma product via 505(b)2 FDA pathway w/ new 20-year IP life

  • Stage Concept Only
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.